<bill session="115" type="hr" number="1154" updated="2019-04-18T15:56:16Z">
  <state datetime="2018-11-16">REFERRED</state>
  <status>
    <introduced datetime="2018-11-16"/>
  </status>
  <introduced datetime="2018-11-16"/>
  <titles>
    <title type="official" as="introduced">Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.</title>
    <title type="display">Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.</title>
  </titles>
  <sponsor bioguide_id="L000567"/>
  <cosponsors>
    <cosponsor bioguide_id="B001251" joined="2018-11-16"/>
    <cosponsor bioguide_id="C001072" joined="2018-11-27"/>
    <cosponsor bioguide_id="E000215" joined="2018-11-16"/>
  </cosponsors>
  <actions>
    <action datetime="2018-11-16">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-11-16" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="sr" session="115" relation="unknown" number="690"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2018-11-16T05:00:00Z" status="Introduced in House">Applauds the growth in research and development into new therapies for rare diseases and the resulting number of FDA-approved therapies for those living with rare diseases, and affirms the need to continue supporting such research and development.

Recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure thousands of rare diseases for which no treatment options are currently available.</summary>
  <committee-reports/>
</bill>
